HOME >> BIOLOGY >> NEWS
Chemical Society announces EPA awards for environmentally friendly technology

ter and are found in many consumer and industrial products, including soaps, laundry and hard surface cleaners. Most surfactants are petroleum-based and some are harmful to the environment. Rhamnolipid biosurfactants are readily biodegradable, demonstrate low toxicity and are produced in a fermentation process from renewable resources. These naturally occurring biosurfactants have been used to recover hydrocarbons from oil sludge, to facilitate petroleum storage tank cleaning and for a wide variety of bioremediation projects. This biosurfactant was recently approved by the EPA for use as a fungicide for the agricultural industry.

Bristol-Myers Squibb Company (New York) This pharmaceutical and health care company developed a better route to paclitaxel, a cancer drug used to treat ovarian and breast cancer. Paclitaxel was first isolated from the bark of the Pacific yew tree. Harvesting the bark meant sacrificing the tree, which provides habitat for the endangered spotted owl. Bristol-Myers Squibb designed a semi-synthetic route to paclitaxel, using a naturally occurring compound found in the European yew's leaves and twigs. Further improvements to the process have led to the synthesis of paclitaxel using Plant Cell Fermentation (PCF) technology. This new process using plant cell cultures saves energy, improves worker safety and eliminates tons of waste.

Buckman Laboratories International, Inc. (Memphis, Tenn.) Recycling can be a sticky business when lingering adhesives on envelopes, magazine binding and other materials gum up the machines used by paper mills to turn recycled waste into new products. When built-up adhesives slow down paper machines, mill operators typically apply toxic solvents to the sticky gunk. But Buckman Laboratories found a novel enzyme to do the job more safely. The company's product, Optimyze, contains an esterase-type enzyme that helps hydrolyze a major adhesive ingredient polyvinyl acetate
'"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
29-Jun-2004


Page: 1 2 3

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Chemical genetics identifies SARS inhibitors
4. Chemical signals health of brain cells Symposium
5. Highlights of American Chemical Society national meeting in Philadelphia, Aug. 22-26
6. Chemical engineers discover filtration system to help biotech industry
7. NIH roadmap for biomedical research focus of chemists at American Chemical Society meeting
8. American Chemical Society media registration
9. NIH launches first center in Nationwide Chemical Genomics Network
10. Chemical reaction in birds provides sense of direction during migratory flights
11. Annual Chemical Biology Symposium at Yale May 14, 2004

Post Your Comments:
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 The ... million in 2013, and is expected to grow ... 2019. , Browse through the TOC of the ... industry trends and segments, with help of various ... The global DNA Microarray market consists of instrument, ...
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
(Date:12/13/2014)... ANTONIO , Dec. 12, 2014  Janssen Research ... data at the San Antonio Breast Cancer Symposium (SABCS) ... plus best supportive care (BSC) versus BSC when used ... receiving standard chemotherapy. This non-inferiority trial did not meet ... 15 percent or greater increase in the risk of ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
Cached News: